title: Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis.
abstract: The aim of this study was to assess the clinical activity and toxicity of liposome-encapsulated doxorubicin citrate (Myocet) in a retrospective multicenter cohort of epithelial ovarian, primary peritoneal, and tubal cancer patients. Records of patients with recurrent epithelial ovarian, primary peritoneal, and tubal cancer treated with liposome-encapsulated doxorubicin citrate (60 mg/m on day 1 of a 21-day cycle) after failure of more than one previous regimen were reviewed. Fifty-three patients were evaluated for efficacy and toxicity. The median age of the patients was 59 (range 39-73). The median follow-up was 6 months (range 1-17). One patient (1.9%) showed a complete response and 13 patients (24.5%) showed a partial response, yielding an overall response rate of 26.4% (14/53 patients). Clinical benefit was achieved in 36 patients (67.9%). The median progression-free survival (PFS) for the entire study population was 4.0 months (range 1.0-14.8). The median PFS for platinum-sensitive and platinum-resistant patients was 4.0 months (ranges 1.0-14.8 and 1.0-9.4, respectively; P=0.652). The median overall survival from the start of liposome-encapsulated doxorubicin citrate was 10.0 months. Multivariate survival analysis showed no association between the liposome-encapsulated doxorubicin citrate line of treatment or platinum sensitivity to PFS in age and BRCA status-adjusted models. Only 11.3% of patients experienced grade 3-4 hematologic toxicities, 80% grade-2 alopecia, and 50% grade-1-2 fatigue. No other grade-4 toxicities, no significant cardiac events, or hand and foot syndromes were reported. Liposome-encapsulated doxorubicin citrate was well tolerated, with a good response and high clinical benefit rate. Further evaluation in a larger prospective cohort is warranted.
authors.affiliation: aRabin Medical Center, Petach Tikva bMeir Medical Center, Kfar Saba cTel Aviv Souraski Medical Center, Tel Aviv, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv dSoroka Medical Center, Beer Sheva, affiliated with Ben-Gurion University of the Negev, Beer Sheva eNaharia Medical Center, Naharia fRambam Medical Center, Haifa gLin Medical Center, Haifa, affiliated with the Faculty of Medicine, the Technion Israel Institute of Technology, Haifa hZiv Medical Center, Safed iShaare Zedek Medical Center, Jerusalem, affiliated with the Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel jNew York University Cancer Institute, NYU School of Medicine, New York, New York, USA.
authors.forename: Ram
authors.initials: R
authors.lastname: Eitan
authors.forename: Ami
authors.initials: A
authors.lastname: Fishman
authors.forename: Michai
authors.initials: M
authors.lastname: Meirovitz
authors.forename: Hadassah
authors.initials: H
authors.lastname: Goldenberg
authors.forename: Amnon
authors.initials: A
authors.lastname: Amit
authors.forename: Claude
authors.initials: C
authors.lastname: Koren
authors.forename: Yulia
authors.initials: Y
authors.lastname: Schneider
authors.forename: Ora
authors.initials: O
authors.lastname: Rosengarten
authors.forename: Avivit
authors.initials: A
authors.lastname: Neuman
authors.forename: Shoshanna
authors.initials: S
authors.lastname: Keren-Rosenberg
authors.forename: Tamar
authors.initials: T
authors.lastname: Safra
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin